Santiago PV, Lozano BDM, Patiño GS, Gaviria JLM, Rendón HJ

Language: Spanish
References: 10
Page: 365-372
PDF size: 325.88 Kb.

ABSTRACT

Systemic Epstein-Barr virus-positive T cell Iymphoproliferative disease of childhood is a recently described, potentially lethal clinical entity in children and young adults, characterized by a clonal proliferation of EBV-infected T-cells with an activated cytotoxic phenotype. It is typically prevalent in Asian countries and Mexico, and its incidence is unknown in our country. This report describes a case of systemic Epstein-Barr virus positive T-cell lymphoproliferative disease of childhood with idle progression and fatal outcome.

REFERENCES

1. Quintanilla-Martinez L, Kimura H, Jaffe ES. EBVpositive T-cell lymphoproliferative disorders of childhood. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4th). Lyon: IARC; 2008.

2. Quintanilla-Martinez L, Kumar S, Fend F, Reyes E, Teruya-Feldstein J, Kingma DW, et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood 2000; 96: 443-451.

3. Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 2009; 20: 1472-1482.

4. Ohshima K, Kimura H, Yoshino T, Kim CW, Ko YH, Lee SS, et al. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int 2008; 58: 209-217.

5. Kasahara Y, Yachie A, Takei K, Kanegane C, Okada K, Ohta K, et al. Differential cellular targets of Epstein- Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001; 98: 1882-1888.

6. Rodriguez-Pinilla SM, Barrionuevo C, Garcia J, de los Angeles M, Pajares R, Casavilca S, et al. Epstein- Barr virus-positive systemic NK/T-cell lymphomas in children: report of six cases. Histopathology 2011; 59: 1183-1193.

7. Chuang HC, Lay JD, Chuang SE, Hsieh WC, Chang Y, Su IJ. Epstein-Barr virus (EBV) latent membrane protein-1 down-regulates tumor necrosis factor-alpha (TNF-alpha) receptor-1 and confers resistance to TNF-alpha-induced apoptosis in T cells: implication for the progression to T-cell lymphoma in EBV-associated hemophagocytic syndrome. Am J Pathol 2007; 170: 1607-1617.

8. Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 2003; 187: 527-533.

9. Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, Kojima S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 2012; 119: 673-686.

10. Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood 2011; 117: 5835-5849.